Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the drug registration certificates of Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injectable Ranitidine Acetate, indicating a significant advancement in its product portfolio for hypertension treatment [1] Group 1: Product Approval - The company has obtained the drug registration certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II), which is intended for the treatment of hypertension [1] - This product is not suitable for initial treatment of hypertension but is applicable for adults with primary hypertension whose blood pressure cannot be effectively controlled by either Candesartan Cilexetil or Hydrochlorothiazide alone, or as a replacement therapy for the combination of both drugs at the same dosage [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2025年9月22日（星期一）16:00-17:00； ●会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）； ●会议召开方式：上证路演中心网络互动； ● 投资者可于2025年9月15日（星期一）至9月19日（星期五）16:00前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600521@huahaipharm.com进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 浙江华海药业股份有限公司（以下简称"公司"）已于2025年8月26日发布公司2025年半年度报告，为便 于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年9月22日 （星期一）16:00-17:00举行2025年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-099 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 15 日（星期一）至 9 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江华海药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 22 日（星期一）16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的 ...

Core Insights - The market demand for chitosan is increasing due to growing concerns about food safety, healthcare, and environmental protection, with the market size in China projected to reach 758 million yuan in 2024, representing a year-on-year growth of 19.37% [1][7]. Industry Overview - Chitosan is a natural biodegradable biopolymer derived from chitin, primarily sourced from the shells of crustaceans and certain fungi and plants [2][4]. - The unique physical and chemical properties of chitosan, influenced by its degree of deacetylation, allow for a wide range of applications across various sectors [2][4]. Industry Chain - The upstream of the chitosan industry includes raw materials such as crustacean shells, insects, fungi, and chemicals like hydrochloric acid and sodium hydroxide [5]. - The midstream involves the production and manufacturing of chitosan, while the downstream applications span pharmaceuticals, food preservation, cosmetics, environmental protection, agriculture, textiles, and paper [5][6]. Market Size - The chitosan industry in China is expected to grow significantly, with applications in food preservation, medical materials, and as an eco-friendly alternative to traditional plastics [1][7]. Key Companies - Jiangsu Kangting Biotechnology Co., Ltd. is a major player in the chitosan industry, focusing on research, production, and sales, with a wide range of applications in health foods, medical devices, and agriculture [8][9]. - Shandong Weikang Biomedical Technology Co., Ltd. specializes in marine sugar bioengineering, emphasizing research and development in chitosan and its derivatives [9]. Industry Development Trends 1. Continuous technological innovation is crucial for industry upgrades, with new extraction methods like enzyme extraction and supercritical fluid extraction expected to replace traditional methods [10][11]. 2. The application of chitosan is expanding into emerging fields beyond traditional sectors, including its use as a natural preservative and in high-end medical products [10][11]. 3. The industry's strategic value is highlighted by the push for sustainable development and carbon neutrality, with international competition driving technological upgrades and collaborations [11].

Market Overview - The convertible bond market showed positive performance with the Zhongzheng Convertible Bond Index rising by 1.23% to 480.25, with a total trading volume of 76.871 billion [1] - A total of 437 convertible bonds were traded, with 409 increasing in value, 1 remaining flat, and 27 declining [1] Top Performing Convertible Bonds - The top five performing convertible bonds included: - Fushi Convertible Bond (123217) with a rise of 20.0% - Jing 23 Convertible Bond (113669) also up by 20.0% - Jiazhe Convertible Bond (113039) increasing by 17.69% - Chongda Convertible Bond 2 (128131) up by 14.01% - Outong Convertible Bond (not specified) rising by 11.67% [2] Underperforming Convertible Bonds - The five convertible bonds with the largest declines were: - Kaizhong Convertible Bond (113698) down by 3.29% - Yaoshi Convertible Bond (123145) decreasing by 2.92% - Titan Convertible Bond (127096) falling by 2.69% - Huicheng Convertible Bond (not specified) down by 2.04% [2] Corresponding Stock Performance - Among the stocks corresponding to the convertible bonds, 352 stocks rose, 16 remained flat, and 69 declined [1] - The top five performing stocks included: - Si Hui Fushi (300852) with a rise of 19.99% - Jingke Technology (601778) increasing by 10.05% - Chongda Technology (002815) up by 10.01% - Luxshare Precision (not specified) rising by 10.00% - Jingwang Electronics (not specified) also up by 10.00% [4] Declining Stocks - The stocks with the largest declines included: - Titan Shares (not specified) down by 5.64% - Huahai Pharmaceutical (not specified) decreasing by 4.26% - Nenghui Technology (not specified) down by 3.88% - Shouhua Gas (not specified) falling by 2.99% - Shandong Zhanggu (not specified) down by 2.98% [5]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

Market Performance - The pharmaceutical sector experienced a decline of -1.91% on September 9, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 28th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, pharmaceutical distribution (-0.52%), blood products (-0.62%), and in vitro diagnostics (-0.73%) performed relatively better, while medical R&D outsourcing (-3.63%), medical devices (-2.47%), and medical consumables (-2.06%) lagged behind [1] - Top three gainers included Rongchang Bio (+11.92%), Hehua Co. (+10.07%), and Zhend Medical (+10.00%), while the largest decliners were Yifang Bio (-11.74%), Huahai Pharmaceutical (-10.00%), and Chenxin Pharmaceutical (-8.42%) [1] Industry News - BMS announced positive results from the Phase II clinical trial of Pumitamig, a bispecific antibody developed in collaboration with BioNTech for the treatment of extensive-stage small cell lung cancer (ES-SCLC), showing a confirmed objective response rate (cORR) of 76.3% and a disease control rate (DCR) of 100% [2] - Pumitamig targets PD-L1 and VEGF-A, designed to restore the function of effector T cells in the tumor microenvironment while locally neutralizing the effects of VEGF-A [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration for its product, Eicosapentaenoic Acid Ethyl Ester Soft Capsules, to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [3] - Taiji Group (600129) reported that its subsidiary Fuling Pharmaceutical Factory received a clinical trial approval notice for Semaglutide injection for the treatment of type 2 diabetes [3] - Huahai Pharmaceutical (600521) disclosed that its subsidiary Huahai Jiancheng underwent a pre-approval inspection by the FDA from July 14 to 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin, which met the CGMP requirements [3] - Dongfang Bio (688298) announced that its subsidiary Laihe Bio obtained a Class III medical device registration certificate for its influenza virus antigen detection kit (colloidal gold method), enhancing the company's product portfolio in the respiratory joint detection field [3]

Group 1 - The company Zhejiang Huahai Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., passed the FDA pre-approval inspection, confirming compliance with CGMP requirements [1][2] - The inspection took place from July 14 to July 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin [1][2] - Gabapentin is a widely prescribed medication for epilepsy and neuropathic pain, indicating its significant role in the global pharmaceutical market [1][2] Group 2 - The successful FDA inspection enhances the company's core competitiveness and supports its ongoing international market expansion [2] - The company has registered its Gabapentin products in multiple countries, including Europe, the United States, and South Korea, ensuring a stable market presence [1][2]

Group 1 - The core point of the announcement is that Zhejiang Huahai Pharmaceutical Co., Ltd.'s subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., successfully passed the FDA's pre-approval inspection, indicating compliance with the FDA's quality management system requirements [1][2] - The inspection took place from July 14 to July 18, 2025, covering the overall quality management system of the factory and the active pharmaceutical ingredient Gabapentin [1] - The inspection result was classified as NAI (No Action Indicated), which signifies zero defects in the inspection [1] Group 2 - The successful FDA inspection enhances the company's ability to expand in international markets and positively impacts its core competitiveness and sustainable development [2] - Gabapentin, primarily used for treating epilepsy and neuropathic pain, is one of the most prescribed drugs globally, indicating its significant role in the pharmaceutical market [1][2] - The company's Gabapentin active pharmaceutical ingredient is already registered in multiple countries, including Europe, the United States, and South Korea [1]

Group 1 - The chemical pharmaceutical sector experienced a downturn on September 9, with several companies facing significant declines [1] - Huahai Pharmaceutical hit the daily limit down, indicating a severe drop in stock price [1] - Other companies such as Yifang Bio-U, Chenxin Pharmaceutical, Jiankai Technology, Huana Pharmaceutical, Lifang Pharmaceutical, and Baili Tianheng also saw declines in their stock prices [1]